Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.79 |
| ▸ | TNKS | O95271 | 3/20 | 0.77 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.77 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 0.66 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474012 | 0.91 | PARP1 (0.89) | PARP1TNKSTNKS2 | |
| SCHEMBL30293105 | 0.91 | PARP1 (0.89) | PARP1TNKSTNKS2 | |
| SCHEMBL15204765 | 0.88 | PARP1 (0.85) | PARP1TNKSTNKS2 | |
| SCHEMBL22829824 | 0.88 | PARP1 (1.00) | PARP1TNKSTNKS2 | |
| SCHEMBL15846050 | 0.88 | PARP1 (0.78) | PARP1TNKSTNKS2PRAP1PARP2 | |
| SCHEMBL16571494 | 0.88 | PARP1 (0.71) | PARP1TNKSTNKS2PRAP1PARP2 | |
| SCHEMBL16571982 | 0.88 | PARP1 (0.71) | PARP1TNKSTNKS2PRAP1PARP2 | |
| SCHEMBL30546123 | 0.87 | PARP1 (0.61) | PARP1TNKSTNKS2PRAP1PARP2 | |
| SCHEMBL26120544 | 0.87 | PARP1 (0.61) | PARP1TNKSTNKS2PRAP1PARP2 | |
| SCHEMBL22829810 | 0.87 | PARP1 (1.00) | PARP1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598418-B2 | Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 | CADILA HEALTHCARE LIMITED (IN) | 2017-03-21 | — | — | US | disclosed |
| US-9598418-B2 | Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 | CADILA HEALTHCARE LIMITED (IN) | 2017-03-21 | — | — | US | disclosed |
| US-9598418-B2 | Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 | CADILA HEALTHCARE LIMITED (IN) | 2017-03-21 | — | — | US | disclosed |
| EP-2938598-B1 | SUBSTITUTED PHTHALAZIN-1(2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| EP-2938598-B1 | SUBSTITUTED PHTHALAZIN-1(2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| EP-2938598-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | Cadila Healthcare Limited (IN) | 2015-11-04 | — | — | EP | disclosed |
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LIMITED (IN) | 2015-10-15 | — | — | US | disclosed |
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LIMITED (IN) | 2015-10-15 | — | — | US | disclosed |
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LIMITED (IN) | 2015-10-15 | — | — | US | disclosed |
| WO-2014102817-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LIMITED (IN) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014102817-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LIMITED (IN) | 2014-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | PARP1, PARP11, PARP2 | PARP1 1/4885TNKS 15/4885TNKS2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.